Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68-Gallium-DOTATATE-PET/CT in Metastatic Thyroid Cancer
NCT04927416Phase 2Recruiting
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases
- Start
- Oct 2021
- Primary completion
- Nov 2030
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of gallium ga 68 dotatate in thyroid cancer (3 arms), sponsored by National Institute of Diabetes and Digestive and Kidney Diseases. Primary endpoint: Prevalence of patients with metastatic RAI-non-avid or RAI-non-responsive thyroid cancer whose tumors are characterized by a high SSTR2 expression. Started Oct 2021; status: recruiting.
02
Drugs
gallium ga 68 dotatate
03
Conditions
thyroid cancer
Beyond the preview
Go deeper on NCT04927416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04927416.